lulizumab pegol (BMS-931699) / BMS  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lulizumab pegol (BMS-931699) / BMS
NCT02843659 / 2016-000101-37: Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Terminated
2
45
US, Europe, RoW
BMS-931699, lulizumab, BMS-986142, Placebo
Bristol-Myers Squibb
Sjögren's Syndrome
07/17
07/17
NCT02265744 / 2014-002184-14: Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

Completed
2
730
Europe, Canada, Japan, US, RoW
BMS-931699, lulizumab pegol, Placebo matching BMS-931699
Bristol-Myers Squibb
Lupus
10/17
11/17
NCT04903054: Selective CD28 Blockade in Renal Transplant Recipients

Withdrawn
2
54
US
Lulizumab, BMS-931699, anti-CD28 domain antibody (anti-CD28 dAb), Tacrolimus, Prograf®, Thymoglobulin®, antithymocyte globulin, Methylprednisolone, corticosteroid, Mycophenolate Mofetil, MMF, CellCept®, Prednisone
National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb, PPD
Kidney Transplantation, Renal Transplant Recipients
09/22
09/22
NCT04066114: Treg Modulation With CD28 and IL-6 Receptor Antagonists

Completed
1/2
10
US
lulizumab pegol, BMS-931699, antithymocyte globulin (rabbit), ATG (rabbit), Thymoglobulin®, methylprednisolone, Solu-Medrol ®, tocilizumab, Actemra®, Prednisone, prednisone tablets, Rayos®, everolimus, Zortress®, belatacept, Nulojix®, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, Myfortic®
National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb, Clinical Trials in Organ Transplantation
Living-Donor Kidney Transplant, Kidney Transplant Recipients
09/23
09/23

Download Options